Marmara-1 | Marmara-2 | Central Anatolia | Southern Anatolia | Eastern Anatolia | Total | P | |
---|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||
Prerenal | 164 (65.3) | 99 (93.4) | 53 (63.9) | 170 (74.2) | 64 (59.8) | 550 (70.9) | p < 0.001 |
Dehydration | 104 (41.4) | 78 (73.6) | 42 (50.6) | 83 (36.2) | 33 (30.8) | 340 (43.8) | |
Heart failure | 32 (12.7) | 41 (38.7) | 8 (9.6) | 52 (22.7) | 21 (19.6) | 154 (19.8) | |
Burn | 1 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | |
Gastrointestinal loss | 31 (12.4) | 17 (16.0) | 23 (27.7) | 37 (16.2) | 13 (12.1) | 121 (15.6) | |
Liver cirrhosis and ascites | 8 (3.2) | 2 (1.9) | 1 (1.2) | 4 (1.7) | 2 (1.9) | 17 (2.2) | |
Sepsis | 39 (15.5) | 6 (5.7) | 10 (12.0) | 76 (33.2) | 17 (15.9) | 148 (19.1) | |
Renal | 112 (44.6) | 74 (69.8) | 44 (53.0) | 165 (72.1) | 62 (57.9) | 457 (58.9) | p < 0.001 |
Ischemia | 19 (7.6) | 41 (38.7) | 9 (10.8) | 29 (12.7) | 21 (19.6) | 119 (15.3) | |
Nephrotoxic agent | 66 (26.3) | 28 (26.4) | 25 (30.1) | 102 (44.5) | 32 (29.9) | 253 (32.6) | |
Aminoglycoside | 2 (0.8) | 3 (2.8) | 1 (1.2) | 2 (0.9) | 2 (1.9) | 10 (1.3) | |
Colistin | 1 (0.4) | 2 (1.9) | 0 (0.0) | 2 (0.9) | 3 (2.8) | 8 (1.0) | |
Radiocontrast material | 28 (11.2) | 3 (2.8) | 3 (3.6) | 19 (8.3) | 9 (8.4) | 62 (8.0) | |
NSAIDs | 15 (6.0) | 12 (11.3) | 5 (6.0) | 48 (21.0) | 12 (11.2) | 92 (11.9) | |
RAS blocker | 8 (3.2) | 1 (0.9) | 12 (14.5) | 52 (22.7) | 6 (5.6) | 79 (10.2) | |
Chemotherapeutic drugs | 7 (2.8) | 7 (6.6) | 3 (3.6) | 0 (0.0) | 1 (0.9) | 18 (2.3) | |
Others | 12 (4.8) | 9 (8.5) | 14 (16.9) | 35 (15.3) | 6 (5.6) | 76 (9.8) | |
Glomerulonephritis | 12 (4.8) | 8 (7.5) | 4 (4.8) | 15 (6.6) | 0 (0.0) | 39 (5.0) | |
Vasculitis | 5 (2.0) | 0 (0.0) | 7 (8.4) | 5 (2.2) | 0 (0.0) | 17 (2.2) | |
Diabetes mellitus | 21 (8.4) | 14 (13.2) | 1 (1.2) | 63 (27.5) | 5 (4.7) | 104 (13.4) | |
Tubulointerstitial nephritis | 9 (3.6) | 6 (5.7) | 8 (9.6) | 5 (2.2) | 7 (6.5) | 35 (4.5) | |
Postrenal | 41 (16.3) | 16 (15.1) | 15 (18.1) | 19 (8.3) | 14 (13.1) | 105 (13.5) | p = 0.068 |
Stone disease | 12 (4.8) | 2 (1.9) | 4 (4.8) | 1 (0.4) | 4 (3.7) | 23 (3.0) | |
Malignancy | 14 (5.6) | 7 (6.6) | 6 (7.2) | 8 (3.5) | 6 (5.6) | 41 (5.3) | |
Vesicoureteral reflux | 1 (0.4) | 0 (0.0) | 1 (1.2) | 1 (0.4) | 1 (0.9) | 4 (0.5) | |
Prostatic disease | 16 (6.4) | 9 (8.5) | 4 (4.8) | 9 (3.9) | 3 (2.8) | 41 (5.3) | |
Retroperitoneal fibrosis | 0 (0.0) | 0 (0.0) | 1 (1.2) | 0 (0.0) | 1 (0.9) | 2 (0.3) |